Dexcel Pharma Technologies Ltd., 10% Owner at Urovant Sciences Ltd. (UROV), bought 20,162 shares at $8.02 ($162K) on 2019-06-05, disclosed to the SEC on 2019-06-06.
Scheduled purchase ($162k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.02 | 6,540 | $52K | 32.5% |
| 2 | $8.02 | 6,540 | $52K | 32.5% |
| 3 | $8.00 | 7,082 | $57K | 35.1% |
| Total | $8.01 avg | 20,162 | $162K | 100% |
| Filing → |
| UROV | BUY | 2019-06-19 | $262K | — | Filing → |
| UROV | BUY | 2019-06-14 | $355K | — | Filing → |
| UROV | BUY | 2019-06-11 | $292K | — | Filing → |